PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2023 ENDED MARCH 31, 2023
June 26 2023 - 2:25PM
PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging
biomedical device company focused on the commercialization of
innovative medical therapeutics for companion animals, will report
financial results for the year ending March 31, 2023, on Thursday,
June 29, 2023 after market close. The company will host a
conference call to discuss these results at 4:00 p.m. CT (5:00 p.m.
ET) on the same day.
Attendees of the live webcast of the conference
call and related earnings release materials can register and access
the webcast on PetVivo’s Investor Relations website at:
https://audience.mysequire.com/webinar-view?webinar_id=19521825-9284-4391-bfe3-8ed5b4ec0774
A replay of the webcast will be available
through the same link following the conference call. Participants
can also access the call using the dial-in details below.
Date: Thursday, June 29, 2023 Time: 4:00 p.m. CT (5:00 p.m.
ET)Dial-in: +1 346 248 7799Meeting ID: 92979093556Passcode:
980888
Disclosure Information
PetVivo uses and intends to continue to use its
Investor Relations website as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the company’s Investor Relations website, in addition to
following the company’s press releases, SEC filings, public
conference calls, presentations and webcasts.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is currently
available for commercial sale to veterinarians.
CONTACT:John Lai, CEOPetVivo Holdings,
Inc.Email: info1@petvivo.com(952) 405-6216
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024